GDC-0994: Potent ERK1/2 Inhibitor for Oncology and Liver Research

Executive Summary: GDC-0994 is a small molecule inhibitor targeting ERK1/2 with sub-nanomolar potency (product information). It acts downstream in the MAP kinase pathway, which regulates cell proliferation and survival. Preclinical studies confirm efficacy in KRAS- and BRAF-mutant tumor models and in models of cholestatic liver injury via ERK1/2 phosphorylation inhibition (reference study). The compound is orally bioavailable and suitable for diverse research settings. APExBIO supplies GDC-0994 as SKU B5817, validated for both oncology and hepatology protocols.

Biological Rationale

ERK1/2 (extracellular-signal-regulated kinases 1 and 2) are serine/threonine kinases central to the RAS/RAF/MEK/ERK signaling cascade. This pathway orchestrates cellular proliferation, differentiation, and survival. Dysregulation, often from oncogenic BRAF or RAS mutations, leads to persistent ERK activation and is implicated in multiple cancers (see translational review). Recent mechanistic studies extend the role of ERK1/2 to non-oncologic pathologies such as estrogen-induced cholestatic liver injury, highlighting cross-domain utility (reference study).

Mechanism of Action of GDC-0994

GDC-0994 is a selective, orally bioavailable inhibitor of ERK1/2. It binds to ERK1 with an IC₅₀ of 1.1 nM and to ERK2 with an IC₅₀ of 0.3 nM (APExBIO product data). By blocking ERK1/2 phosphorylation, GDC-0994 prevents activation of downstream effectors such as p90RSK, resulting in suppression of ERK-dependent gene transcription and cellular proliferation. In tumor models, this translates to reduced viability of KRAS- and BRAF-mutant cells. In hepatic models, ERK1/2 inhibition interrupts the pathological signaling that drives bile acid transporter dysregulation and cholestatic injury (reference study).

Evidence & Benchmarks

• GDC-0994 inhibits ERK1 (IC₅₀ = 1.1 nM) and ERK2 (IC₅₀ = 0.3 nM) enzyme activity, as measured in biochemical assays (product data).
• In KRAS- and BRAF-mutant xenograft models, GDC-0994 reduced tumor volume and blocked phosphorylation of p90RSK, a downstream ERK substrate (product data).
• In zebrafish models of psoralen- and isopsoralen-induced cholestatic injury, GDC-0994 rescued bile acid transporter gene expression (abcb11b, slc10a1) and mitigated hepatotoxicity (Chen et al., 2024).
• GDC-0994 shows solubility ≥44.1 mg/mL in DMSO and ≥19.2 mg/mL in ethanol, but is insoluble in water; optimal dissolution may require warming to 37°C or ultrasonic treatment (product data).
• In vitro, GDC-0994 suppressed ERK-dependent cell proliferation in BRAFV600E cell lines, confirming pathway engagement (lab workflow guide).

This article extends the mechanistic scope described in "ERK1/2 Inhibition in Translational Liver Research" by adding domain-bridging experimental evidence and protocol practicalities for APExBIO's GDC-0994.

Applications, Limits & Misconceptions

GDC-0994 is primarily used in preclinical research targeting the MAP kinase pathway in cancer models, especially those with KRAS or BRAF mutations. It is increasingly leveraged in hepatic disease models, notably estrogen-induced cholestasis, due to shared ERK1/2 signaling mechanisms. The compound enables mechanistic studies of pathway inhibition, drug synergy, and resistance mechanisms.

Common Pitfalls or Misconceptions

• GDC-0994 is not active against upstream kinases (RAF, MEK); it is selective for ERK1/2 (product data).
• It is not suitable for in vivo studies requiring water solubility without formulation, due to low aqueous solubility.
• Long-term storage of stock solutions is not recommended; aliquoting and freezing at -20°C are advised to maintain integrity (product info).
• GDC-0994 is for research use only; it is not approved for clinical or diagnostic applications.
• ERK1/2 inhibition may not fully recapitulate pathway blockade in cell lines with compensatory signaling; parallel controls are necessary (protocol analysis).

Workflow Integration & Parameters

• Stock solution preparation: Dissolve GDC-0994 at ≥44.1 mg/mL in DMSO or ≥19.2 mg/mL in ethanol. Warm to 37°C or apply ultrasound for complete dissolution as needed (product info).
• Storage: Store solid GDC-0994 and prepared aliquots at -20°C; avoid long-term storage in solution.
• In vitro dosing: Typical experimental concentrations range from 10 nM to 1 μM, with titration based on assay sensitivity (experimental guide).
• In vivo administration: Oral gavage is supported for rodent models, using vehicle formulations compatible with GDC-0994's solubility.
• Controls: Include untreated, vehicle, and pathway-specific positive controls to confirm ERK pathway engagement.

GDC-0994 (SKU B5817) from APExBIO is referenced in detailed protocol guides, enabling reproducible ERK1/2 inhibition across oncology and hepatic workflows (product page).

Conclusion & Outlook

GDC-0994 is a robust chemical tool for dissecting ERK1/2 signaling in both cancer and cholestatic liver models. Its selectivity and potency allow clear attribution of phenotypic effects to ERK pathway inhibition. Recent studies confirm its ability to reverse ERK1/2-driven hepatic injury, underscoring cross-domain research value (Chen et al., 2024). As protocol standards mature, GDC-0994 is expected to remain a key reference compound for mechanistic and translational studies, with ongoing relevance in both oncology and hepatology research (related mechanistic study).